Hillebrand G, Castro L A, Illner W D, Schleibner S, Land W, Gurland H J
Z Urol Nephrol. 1985 Dec;78(12):667-71.
Animal experiments have demonstrated a synergistic immunosuppressive effect when using the combination of ciclosporin (CS) and azathioprine (AZA) as immunosuppressant. On this basis these drugs were used in patients considered to be at high risk for immunological complications. Group I (immunological risk patients) consisted of 63 patients with a second or third graft and/or elevated cytotoxic antibodies above 30% against the test panel. In addition to the basic immunosuppressive therapy (CS) and methylprednisolone (MP), AZA was given in the first 2 weeks following transplantation. Group II (historical control) summarized immunological risk patients with conventional immunosuppressive therapy (AZA/MP). The IIIrd group with 28 patients on the above mentioned immunological risk were treated with CS and MP only. The results revealed a 2-year actuarial graft survival rate of 68% (groups I) versus 40% (group II) versus 52% (group III). There were no differences in WBC and platelet counts or in infectious complications. No malignancy was noticed.
动物实验表明，将环孢素（CS）和硫唑嘌呤（AZA）联合用作免疫抑制剂时具有协同免疫抑制作用。在此基础上，这些药物被用于被认为有免疫并发症高风险的患者。第一组（免疫风险患者）由63例接受第二次或第三次移植和/或针对测试组细胞毒性抗体升高超过30%的患者组成。除了基础免疫抑制治疗（CS）和甲泼尼龙（MP）外，移植后的前2周还给予AZA。第二组（历史对照）总结了采用传统免疫抑制治疗（AZA/MP）的免疫风险患者。第三组有28例上述免疫风险患者，仅接受CS和MP治疗。结果显示，2年移植精算生存率为：第一组68%，第二组40%，第三组52%。白细胞和血小板计数或感染并发症方面无差异。未发现恶性肿瘤。
